Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients (NCT06407232)
An Interventional Study of Letermovir for Secondary Prophylaxis After Treatment of Cytomegalovirus Infection in High Risk (D+/R-) Kidney and Kidney/Pancreas Transplant Recipients
🩺 Plain-English Summary (8th-Grade Level)
This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.
Who can join: Review the eligibility criteria below.
Location: UW Hospital and Clinics — Madison, Wisconsin
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- UW Hospital and Clinics — Madison, Wisconsin
📞 Contact the Study Coordinator
Phone: (608) 262-2122
Email: sparajuli@medicine.wisc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cytomegalovirus Infections
- Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation — Phoenix, Arizona
- Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients — Guadalajara, Jalisco
- Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients — Boston, Massachusetts
- Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients — Houston, Texas
- Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients — Philadelphia, Pennsylvania
- T Cell Therapy of Opportunistic Cytomegalovirus Infection — Cleveland, Ohio
Explore by condition: All Cytomegalovirus Infections clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.